Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Merck
McKesson
Johnson and Johnson
Harvard Business School
McKinsey

Last Updated: December 11, 2019

DrugPatentWatch Database Preview

Onabotulinumtoxina - Biologic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for onabotulinumtoxina

Identify potential brand extensions & biosimilar entrants

SponsorPhase
University of Wisconsin, MadisonPhase 4
Walter Reed National Military Medical CenterPhase 4
University of Wisconsin, MadisonPhase 1/Phase 2

See all onabotulinumtoxina clinical trials

Pharmacology for onabotulinumtoxina

Company Disclosures: US Patents for onabotulinumtoxina

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Start Trial The Regents of the University of Colorado (Boulder, CO) 2017-07-15 RX company
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
Allergan BOTOX onabotulinumtoxina VIAL; SINGLE-USE 103000 001 1991-12-09   Start Trial Allergan, Inc. (Irvine, CA) 2013-12-28 RX company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for onabotulinumtoxina

These patents were identified by searching patent claims

Supplementary Protection Certificates for onabotulinumtoxina

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
13/025 Ireland   Start Trial PRODUCT NAME: BOTULINUM TOXIN TYPE A; NAT REGISTRATION NO/DATE: PA0148/060/001 20130117; FIRST REGISTRATION NO/DATE: PA018/060/002 17/01/2013 IRELAND PA0148/060/003 17/01/2013 FINLAND 25162 16/01/2013 FINLAND 15424 16/01/2013 FINLAND 28146 20130116
/2013 Austria   Start Trial PRODUCT NAME: BOTULINUMTOXIN TYP A; REGISTRATION NO/DATE: 2-00358; 1-23699; 2-00381 20130117
0654 Netherlands   Start Trial DETAILS ASSIGNMENT: VERANDERING VAN EIGENAAR(S), OVERDRACHT
C/GB12/053 United Kingdom   Start Trial PRODUCT NAME: BOTULINUM TOXIN; REGISTERED: UK PL 00426/0074-0110 20120924; UK PL 00426/0118-0030 20120924; UK PL 00426/0119-0012 20120924; REASON FOR LAPSE: SURRENDERED
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Merck
Harvard Business School
Express Scripts
Colorcon
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.